美国食品药品监督管理局批准第四种无细胞百日咳疫苗用于婴幼儿。
FDA approval of a fourth acellular pertussis vaccine for use among infants and young children.
出版信息
MMWR Morb Mortal Wkly Rep. 1998 Nov 6;47(43):934-6.
PMID:9822368
Abstract
On July 29, 1998, the Food and Drug Administration (FDA) licensed North American Vaccine, Inc. (Beltsville, Maryland) to distribute a combined diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Certiva) for the first four doses of the diphtheria and tetanus toxoids and pertussis vaccination series administered to infants and children aged 6 weeks-6 years. Certiva is the fourth acellular pertussis vaccine to be licensed for use in infants and young children in the United States.
摘要
1998年7月29日，美国食品药品监督管理局（FDA）批准北美疫苗公司（位于马里兰州贝尔茨维尔）销售白喉破伤风类毒素和无细胞百日咳联合疫苗（DTaP）（商品名Certiva），用于6周龄至6岁婴幼儿白喉破伤风类毒素和百日咳疫苗接种系列的前四剂。Certiva是美国批准用于婴幼儿的第四种无细胞百日咳疫苗。
Zotero 插件